Patent · US Active

Optimized HIV envelope gene and expression thereof

US10792357B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignee

International AIDS Vaccine Initiative, Inc. · US

Inventors

Christopher L. Parks · Boonton, US
Maoli Yuan · Brooklyn, US
Xinsheng Zhang · Merrick, US
Aaron Wilson · Montréal, CA
Angela Grazia Lombardo · New York, US
Eddy Sayeed · New York, US
Josephine Helena Cox · New York, US
Takashi Hironaka · Ibaraki, JP
Makoto Inoue · Tokyo, JP
Hiroto Hara · Machida, JP

Key dates

Filing date	Mar 4, 2019
Grant date	Oct 6, 2020
Priority date	—
Expiry date	Mar 4, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/20243
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.